Clinical Characteristics and Short-Term Outcomes of Severe Patients with COVID-19 in Wuhan, China

Introduction

An outbreak of pneumonia caused by a novel coronavirus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), centered in Wuhan, Hubei province, in December 2019.[1] It has rapidly spread to other cities and countries outside Wuhan and has become a global health crisis. As the disease progresses, more and more characteristics about the disease are known to us. Up to now, there are still no specific drugs, mainly supporting treatment in clinic. A large number of studies have shown that the main symptom of this disease was fever, cough and dyspnea.[2-5] Some articles have described the disease in details. Huang et al described epidemiological, clinical, laboratory, and radiological characteristics, treatment, and outcomes of 41 patients that were first group admitted hospital patients and diagnosed with SARS-CoV-2 infection, and they also compared the clinical characteristic between intensive care unit (ICU) and non-ICU patients.[2] Yang et al made a detailed analysis about the patients with critically ill with SARS-CoV-2 infection.[5] Jin et al descripted the characteristics of 74 cases of coronavirus infected disease 2019 (COVID-19) with gastrointestinal symptoms and proposed that non-classical symptoms have been overlooked, posing a threat to the public.[6] Wu et al discussed that older people (⩾65 years old) with greater risk of development of acute respiratory distress syndrome (ARDS) and death.[7] Guo et al found that diabetes is a risk factor for the patients with COVID-19.[8] However, few studies took prospective study to explore the short-term outcomes of severe ill patients under current medical treatment and the risk factors that affect the short-term outcomes of severe ill patients, especially pneumonia patients with certain chronic diseases, which accounted for the majority of deaths. Here, we used a single-centered, prospective method to describe the basic clinical characteristics and short-term outcomes of severe patients in Union hospital, Wuhan, and further explore the potential risk factors for poor outcome through Cox proportional hazard models.

Methods

Results

Clinical Outcomes

A total of 114 patients with COVID-19 were enrolled in this study. At 28 days after severe ill diagnosis, 94 patients were considered as had good outcome while 20 patients had poor outcome. As shown in Figure 1, 51 (45%) patients were alive and discharge, 39 (34%) turned to non-severe ill, 4 (3%) remained severe status and ventilator free, 11 (10%) were alive but still ventilated and 9 (8%) patients had died.

• Download figure
• Open in new tab

Figure 1.

Distribution of short-term (28 days) outcomes of severe ill patients with COVID-19 (N=114).

Prediction of risk factors for severe COVID-19 in poor outcome group

Table 5-6 displayed the results of univariate and multivariate Cox analyses of potential factors for short-term outcomes in severe patients with COVID-19. Our results indicated that, for severe patients, higher levels of oxygen saturation (HR, 0.123; 95% CI, 0.041-0.369), albumin (HR, 0.060; 95% CI, 0.008-0.460) and arterial partial pressure of oxygen (HR, 0.321; 95% CI, 0.106-0.973) were associated with decreased risk of developing poor outcome within 28 days. In the other hand, higher levels of leucocytes (HR, 5.575; 95% CI, 2.080- 14.943), neutrophils (HR, 2.566; 95% CI, 1.022-6.443), total bilirubin (HR, 6.171; 95% CI, 2.458-15.496), globulin (HR, 2.526; 95% CI, 1.027-6.211), blood urea nitrogen (HR, 5.640; 95% CI, 2.193-14.509), creatine kinase-MB (HR, 3.032; 95% CI, 1.203-7.644), lactate dehydrogenase (HR, 4.607; 95% CI, 1.057-20.090), hypersensitive cardiac troponin I (HR, 5.023; 95% CI, 1.921-13.136), lactate concentration (HR,15.721; 95% CI, 2.099-117.777), Interleukin-10 (HR, 3.551; 95% CI, 1.280-9.857) and C-reactive protein (HR, 5.275; 95% CI, 1.517-18.344) were associated with increased risk of poor outcome development. For all the factors analyzed above, increased concentration of lactate (≥ 1.6mmol/L) and total bilirubin (≥ 19.0 μmol/L) might be the most important predictors of poor outcome in the early stage. Furthermore, we found that there was a nonlinear dose-response relationship between ten indices and poor outcome risk, which is depicted in Figure 2.

View this table:

• View inline
• View popup
• Download powerpoint

Table 5.

Univariate and multivariate analyses of potential factors (demographic and epidemiologic) predicting poor outcome

View this table:

• View inline
• View popup

Table 6.

Univariate and multivariate analyses of potential factors (laboratory indexes) predicting poor outcome

• Download figure
• Open in new tab

Figure 2.

Nonlinear dose-response relationship between ten indices and poor outcome risk. Hazard ratios (HRs) were adjusted for age and gender. Dotted lines represent the 95% CIs for the fitted trend. (A) Leucocytes (×10⁹ /L), referent (HR =1): 9.5; (B) Neutrophils (×10⁹ /L), referent: 6.3; (C) Total bilirubin (μmol/L), referent: 19.0; (D) Albumin, referent: 35.0 (g/L); (E) Globulin (g/L), referent: 30.0; (F)Blood urea nitrogen (mmol/L), referent: 8.2; (G) CK- MB (U/L), referent: 24.0; (H) Lactate dehydrogenase (U/L), referent: 245; (I) Hypersensitive cardiac troponin I (ng/L), referent: 26.2; (J)Lactate (mmol/L), referent: 1.6.

Discussion

SARS-CoV-2 has now spread globally and seriously threaten the human health. Demographics and Characteristics of COVID-19 has been gradually investigated and explored by many scientists. Studies had shown that 20% of COVID-19 patients developed to critically disease due to hypoxia or respiratory failure, among them, 5% needed to treat in intensive care unit and 15% required oxygen and essential care. This suggests that this is particularly important in understanding this part of the patient.[9] [10] Recently, Dong et al found that children, in particular, infants developed into severe outcomes. This indicated that patients of any age could develop to severe illness.[11] Feng et al found that severe and critical patients with the typical characteristics of multiple organ and immune function dysfunction. They also found that older people with age (≥ 75 years) was a risk factor for mortality.[12] With the increase number of asymptomatic infectious patients, take measures to detect and isolate early are especially important. In our study, we take a short-term method to prospectively study the reported the epidemiology and risk factors of 114 severe patients with COVID-19 from Union hospital, Hubei province. To our knowledge, this is the first report to describes the severe patients with COVID-19 during a short-term observation and predicted some risk factors for final outcome. In our study, the average age of severe patients swere 63.96 ± 13.41 years and 58 (50.9%) were older than 65 years, the patients are older than in other studies.[5, 13, 14] We also found that 78 (68.4%) of 114 patients were had fever at initial, this was in accordance with previous studies, which fever is the one of the most common symptom in patients who had COVID-19.[5, 14-16] But, 36 (31.6%) of 114 severe patients who were had not fever at the beginning of illness, therefore, other clinical manifestations should be concerned. In recently, Jin et al found that attention should also pay on people who had gastrointestinal symptoms.[6] Mao et al indicated that patients with Neurologic manifestations, clinicians should suspect COVID-19.[14]

According to results from laboratory tests, poor outcome group had lower lymphocytes than good outcome group [0.67 (0.43-0.89) vs. 0.92 (0.70-1.43)]. As is known to all, lymphocytes are the main fighting force against the virus, we suspected that SARS-CoV-2 viral damages on the lymphocyte and causes its reduction.[17] Chen et al found that severe lymphopenia were persistent and more in dead patients than recovered patients and they suggested that a lymphopenia may associated with poor outcome.[18] Tan et al demonstrated a oppose result that lymphopenia is an effective indicator for the severity of patients with COVID-19.[19] CD8+ T cells were significantly lower in poor outcome group. Chen et al indicated that the SARS-CoV-2 infection may affect CD4+ and CD8+ T lymphocytes cells particularly and argue that this is potential correlation with COVID-19 severity.[20] In addition, markedly higher concentrations of cardiac troponin I, creatine kinase, lactate dehydrogenase could be observed in poor outcome group than in their counterpart. Most notably, patients who had poor outcome may develop pulmonary and extra-pulmonary organ damage, including septic shock, acute respiratory distress syndrome, acute kidney injury, acute cardiac injury as well as disseminated intravascular coagulation. Fatality risk of COVID-19 patients with or without history of previous cardiovascular disease may the acute cardiac injury and heart failure.[18] Costanza Emanueli et al suggested that the COVID-19 crisis will have a longer term residual repercussions on the cardiovascular system.[21] This suggestion that the cardiac injury also requires special attention. In our study, we also found that lactate concentration was higher in poor outcome than their counterpart. As with all known, lactate is generally the end product of energy through anaerobic metabolism, and the elevation of lactate level is mainly caused by the increase of blood oxygen deficiency and anaerobic metabolism, this result is consistent with the lower oxygen saturation in poor group, this indicated that lactate level was an important predictors of poor outcome in the early stage. In addition, total bilirubin was also an important predictor of poor outcome in the early stage. Qi recommend that dynamic monitor the liver function of patients is necessary.[22] Cai conclude that patients with abnormal liver function may had higher risks to progress to severe disease.[23] Due to the “cytokine storm” also observed in poor outcome group, 19 (95.0%) of these patients were given glucocorticoid therapy. Wu et al previously found that the administration of methylprednisolone may have reduced the risk of death in patients with ARDS.[7] To our surprise, most of the severe patients treated with Traditional Chinese medicine (TCM) were eventually converted to good outcome, indicated this important effort on COVID-19. A large of clinical practice results indicated that TCM shows significant role in the patients with COVID-19. For the severe patients in the treatment of TCM, the mean length in hospital and the time of nucleic acid turning negative has been shortened by more than 2 days.[24] Yao et al. and Lu et al. analyzed the effect of Lian Hua Qing Wen Capsule in treatment of COVID- 19 patients and they found that this TCM could markedly relieve fever and cough and can promote the recovery.[25] Besides, the comprehensive evaluation and scientific research should be carried out on the effect of TCM on COVID-19.

Meantime, the risk factors related to the poor outcome included uncontrolled inflammation responses, infection, liver and kidney, cardiac dysfunction and hypoxia. The pathogenesis of COVID-19 is still studying. Cytokine storm and uncontrolled inflammation responses are thought to play important roles in the outcome of COVID-19.[26-30] External stimuli resulted to excessive immune response and the pathogenesis of the cytokine storm is complex which leaded to rapid disease progresses and high mortality. The inflammatory cytokine storm is closely correlated to the development and progression of ARDS.[31] Neutrophils play important role in chemokines and cytokines.[32] In our study, poor outcome had significantly higher neutrophil counts than good outcome group, which may leading to the cytokine storm. In addition, CD8+ T cells were significantly lower in poor outcome group. These results mean the important roles of CD8 T cells in COVID-19. Studies had shown that T-cell could inhibit the over-activation of innate immunity.[33] T cells can help to clear the SARS-CoV, and low T-cell response can result in pathological changes in mice with SARS- CoV.[34] The relevant mechanisms need to be further studied.

This study has some limitations. First, owing to the limited number of cases, only 114 severe patients were included. Second, this study was a single-center research and a larger cohort study of severe patients with SARS-CoV-2 from other cities in China and other countries would help to further describe the clinical characteristics and predict the risk factors about this disease.

In summary, we firstly reported this single-centered, prospective, observational study for short-term in severe patients with COVID-19. We found from univariate and multivariate Cox model that cytokine storm and uncontrolled inflammation responses, liver, kidney, cardiac dysfunction may play important roles in final outcome of severe ill patients with COVID-19. This will help clinicians to diagnose and treat severe patients.

Author contributions

Cao Yang and Wei Yang designed the study and had full access to all data in the study and take responsibility for the integrity of data and the accuracy of the data analysis. Xiaobo Feng and Liang Ma contributed to data collection, literature searches, and writing of the manuscript. Xiaobo Feng and Peiyun Li had roles in data analysis and data interpretation. All authors contributed to data acquisition, clinical management, and reviewed and approved the final version of the manuscript. Xiaobo Feng, Peiyun Li and Liang Ma share first authorship and Cao Yang and Wei Yang are co-corresponding authors; the order in which they are listed was determined by workload.

Declaration of interests

We declare no competing interests.